Levita® Magnetics Wins FDA Clearance for Pioneering MARS™ System
MOUNTAIN VIEW, Calif., Aug. 22, 2023 /PRNewswire/ -- Levita Magnetics, whose mission is to help more patients get access to better surgery, announced today it has received U.S. Food and Drug Administration (FDA) clearance for its MARS™ platform.
- The Levita MARS system is a first-of-its-kind minimally invasive surgical platform aimed at the high-volume abdominal surgery market.
- MARS is poised to revolutionize surgical options for a broad range of patients," said Dr. Alberto Rodriguez-Navarro, surgeon, founder, and CEO of Levita Magnetics.
- "With this FDA clearance, we eagerly anticipate making a substantial impact across the value chain."
- "Levita's system can aid in surgeon proficiency and efficiency, and can reduce the need for assistive personnel, signaling a major achievement not only for Levita but for surgical care."